Where to buy DSIP.

DSIP has one of the widest gaps between marketing claim and published evidence of any peptide on the market. It was isolated in 1977, still gets sold as a sleep aid in 2026, and has zero modern Western controlled trials behind it. Where to buy DSIP means picking a vendor who’ll be honest with you about that gap. We’ll walk you through what to look for.

What you’re actually buying

DSIP is a chain of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE for short). No modifications, no cyclic structure, no D-amino acids. It’s about as simple as a synthetic peptide gets.

Swiss researchers Schoenenberger and Monnier isolated it in 1977 from rabbit blood collected during electrically-induced sleep. That’s where the name comes from. The 1977 paper reported that DSIP increased delta-wave sleep in rabbits.

Modern work has revised the picture. A 2024 study built a fusion peptide to help DSIP cross the blood-brain barrier — and found that plain DSIP didn’t work as well as the engineered version (Mu et al., 2024). That’s consistent with a long-standing concern: unmodified DSIP probably doesn’t reach the brain well.

That doesn’t make DSIP fake. It’s a real, structurally defined molecule with a real preclinical literature. It does mean an honest vendor talks about it differently from a vendor leaning on 1977 marketing.

Four buyer checks for DSIP

The general eight peptide-buyer criteria all apply. These four matter more for DSIP:

1. The CAS number must be 62568-57-4

That’s the unique chemical ID for standard DSIP. The CoA should list it on the identity line alongside the WAGGDASGE sequence. Cross-check it against PubChem in 30 seconds. A missing CAS, or one that doesn’t resolve to DSIP, is a critical gap.

2. The target is still unidentified after 50 years

This is the cleanest test of vendor honesty. Multiple decades of work have not located a specific brain target for DSIP — nothing cloned, no high-affinity binding partner confirmed. A vendor whose product page acknowledges this is matching the actual state of the science. A vendor describing DSIP as “the peptide that activates the DSIP target” is overstating it.

3. The sleep evidence is thin

The 1977 paper observed delta-wave sleep in rabbits. That single observation, in one species, in one lab, is the foundation of essentially all DSIP sleep marketing. Some small studies followed in the 1980s and 1990s. No modern randomized controlled trial has tested DSIP for sleep with proper rigor — randomization, blinding, validated polysomnography. Suggestive, not confirmed.

4. The literature has moved away from sleep

The modern Russian preclinical program at the Shemyakin-Ovchinnikov Institute has largely shifted from sleep to stroke reperfusion injury (Tukhovskaya et al., 2021a; Tukhovskaya et al., 2021b). That’s where the recent signal is — not in sleep. A vendor that ignores this and keeps marketing sleep claims is ignoring what the science says.

DSIP

Nonapeptide 9 aa Endogenous

The same compound cited across the modern preclinical literature, including the Tukhovskaya stroke-reperfusion studies and Mu et al. insomnia model. CAS 62568-57-4, ≥99% HPLC purity, ISO 17025 third-party CoA on every lot.

View DSIP

2026 pricing benchmarks

DSIP is one of the simplest peptides on the research market. Just 9 amino acids, no modifications, well-established synthesis. Here’s what we see at research-grade retail in 2026:

• 5 mg vial: $40–$80 per vial. Standard retail size.
• 10 mg vial: $70–$130 per vial. Better per-mg value.
• Multi-vial tiers: 10–20% off for 3- or 6-pack orders.

Below $30 per 5 mg vial deserves a question. The cheap end usually skips HPLC purification, not synthesis steps. Above $100 per 5 mg vial, you’re paying retail markup.

Is DSIP legal to buy?

Yes, easily. DSIP isn’t FDA-approved for any indication, isn’t a controlled substance, isn’t scheduled by the DEA, and isn’t explicitly listed on the WADA 2026 Prohibited List. Research-grade sales operate under 21 CFR § 809.10(b)(9), the Research Use Only labeling rule.

What this simplicity doesn’t protect against: marketing claims. A vendor calling DSIP a “sleep treatment” or “insomnia remedy” is making clinical claims about an unapproved drug. That triggers FDA enforcement regardless of the chemical’s status. The legal product is a research compound. The illegal product is the same chemical sold with human-use claims.

Red flags specific to DSIP

Six warning signs we’d skip:

• Clinical sleep claims. “DSIP treats insomnia.” “DSIP regulates delta-wave sleep.” FDA enforcement territory for an unapproved peptide with no Western RCT base.
• Talking about “the DSIP target.” There isn’t one. 50 years of investigation hasn’t found a specific binding partner. A vendor pretending otherwise is overstating the science.
• Oral capsules, sublingual sprays, or transdermal patches. None validated in any peer-reviewed study. The literature uses injectable or intranasal lyophilized peptide.
• Pre-mixed liquid at room temperature. Powder survives shipping. Liquid degrades fast.
• Missing CAS 62568-57-4 or mass-spec result not at 849.8. Wrong ID, wrong molecule.
• Vendor’s in-house QC instead of third-party testing. Independent ISO/IEC 17025 verification is the research-grade standard.

DSIP

5 mg ≥99% pure Lyophilized

Standard 9-residue nonapeptide, CAS 62568-57-4, sequence WAGGDASGE. The same reference compound used across the modern Russian-school preclinical literature. COA with HPLC trace and mass-spec ships with every order.

Learn more

Frequently asked questions

Is DSIP legal to buy in the USA?

Yes, as a research reference compound. The FDA hasn’t approved DSIP for any indication. It’s not a controlled substance and not on the WADA Prohibited List. Selling DSIP for human consumption is illegal. Buying it as research material isn’t.

Is there evidence DSIP improves sleep?

No modern Western controlled trials of DSIP for sleep, stress, or any other indication have been published in the 2020–2026 window. The marketing rests on the 1977 rabbit isolation and a few small observational studies from earlier decades. No peer-reviewed sleep-trial evidence base has emerged in the modern literature.

Why has the DSIP target never been identified?

Multiple decades of search work have not found a specific brain target for DSIP. The plausible explanations: DSIP acts through indirect mechanisms rather than one high-affinity binding partner, the 1977 isolation may have captured a biological signature without nailing the right molecule, or the active fraction was a breakdown product. The molecular target remains unconfirmed.

What forms of DSIP are sold?

Research-grade DSIP is sold as a lyophilized powder. The preclinical literature has used reconstitution in bacteriostatic water or sterile saline; the 2021 Tukhovskaya stroke studies employed intranasal administration at 120 µg/kg in rodent models. Oral capsules, sublingual sprays, and patches have not been validated in any peer-reviewed study.

How much should DSIP cost?

9 amino acids with no modifications keeps the synthesis cheap. Research-grade pricing typically runs $40–$80 for a 5 mg vial or $70–$130 for 10 mg. Below that range, purity is the likely trade-off; above it, pricing reflects retail margin rather than synthesis cost.

How does DSIP compare to other sleep peptides?

DSIP, Selank, and Epitalon are the three peptides most commonly marketed for sleep. All three share the same evidence problem: substantial Russian preclinical history, very thin Western controlled-trial data, no FDA approval. Standard FDA-approved sleep aids and validated melatonin have much more rigorous human evidence.